E. Armstrong

发表

Thromboprophylactic management in the neurosurgical patient with high risk for both thrombosis and intracranial bleeding

T. Niemi, E. Armstrong, 2010, Current opinion in anaesthesiology.

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

H. Ertl, K. Pasi, R. Herzog, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Platelets significantly modify procoagulant activities in haemophilia A

L. Joutsi-Korhonen, R. Lassila, E. Armstrong, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases

J. Hernesniemi, T. Niemi, E. Armstrong, 2009, Acta Neurochirurgica.

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.

R. Herzog, D. Bellinger, T. Nichols, 2002, Human gene therapy.

Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia.

L. Joutsi-Korhonen, P. Sandset, F. Baghaei, 2011, Seminars in thrombosis and hemostasis.

Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice

K. High, J. Hagstrom, P. Fields, 2001, Gene Therapy.

Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX.

R. Herzog, K. High, O. Cao, 2006, Blood.

Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene.

R. Herzog, K. High, V. Arruda, 2004, Blood.

Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

R. Herzog, K. High, V. Arruda, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Comprehensive re‐evaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function

R. Lassila, T. Szanto, E. Armstrong, 2018, International journal of laboratory hematology.

Management of acute myocardial infarction in a patient with factor XIII deficiency using prophylactic factor replacement therapy

A. Mäkipernaa, R. Lassila, T. Szanto, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Acquired Inhibitors of Coagulation

R. Lassila, E. Armstrong, 2016 .

Successful Liver‐Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H

G. Remuzzi, A. Koivusalo, S. Meri, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.

J. Szer, A. Risitano, H. Schrezenmeier, 2015, The New England journal of medicine.

Current challenges of pharmacovigilance in bleeding disorders: converting the burden to benefit

R. Lassila, E. Armstrong, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.

J. Andersen, I. Sandlie, Stian Foss, 2015, Immunobiology.

Active Online Assessment of Patients Using New Oral Anticoagulants: Bleeding Risk, Compliance, and Coagulation Analysis

L. Joutsi-Korhonen, R. Lassila, E. Armstrong, 2012, Seminars in Thrombosis & Hemostasis.